SE8901115L - Biologiskt aktiva proteiner - Google Patents

Biologiskt aktiva proteiner

Info

Publication number
SE8901115L
SE8901115L SE8901115A SE8901115A SE8901115L SE 8901115 L SE8901115 L SE 8901115L SE 8901115 A SE8901115 A SE 8901115A SE 8901115 A SE8901115 A SE 8901115A SE 8901115 L SE8901115 L SE 8901115L
Authority
SE
Sweden
Prior art keywords
biologically active
active proteins
proteins
febule
tnf
Prior art date
Application number
SE8901115A
Other languages
English (en)
Swedish (sv)
Other versions
SE8901115D0 (sv
Inventor
J-M Dayer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE8901115D0 publication Critical patent/SE8901115D0/xx
Publication of SE8901115L publication Critical patent/SE8901115L/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE8901115A 1988-03-31 1989-03-30 Biologiskt aktiva proteiner SE8901115L (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888807803A GB8807803D0 (en) 1988-03-31 1988-03-31 Biochemical product

Publications (2)

Publication Number Publication Date
SE8901115D0 SE8901115D0 (sv) 1989-03-30
SE8901115L true SE8901115L (sv) 1989-10-01

Family

ID=10634493

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8901115A SE8901115L (sv) 1988-03-31 1989-03-30 Biologiskt aktiva proteiner

Country Status (12)

Country Link
JP (1) JPH02117700A ( )
KR (1) KR890014125A ( )
AU (1) AU3228789A ( )
BE (1) BE1001845A4 ( )
DE (1) DE3910323A1 ( )
DK (1) DK156589A ( )
FR (1) FR2629345A1 ( )
GB (2) GB8807803D0 ( )
IL (1) IL89804A0 ( )
IT (1) IT1232827B ( )
NL (1) NL8900779A ( )
SE (1) SE8901115L ( )

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0393438B1 (de) * 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
CA2485553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (de) * 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992001002A1 (fr) * 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
US5304634A (en) * 1990-10-12 1994-04-19 Hoechst Aktiengesellschaft Inhibitors for the formation of tumor necrosis factor
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
WO1993004375A1 (en) * 1991-08-23 1993-03-04 Nchip, Inc. Burn-in technologies for unpackaged integrated circuits
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
AU5696198A (en) 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DK2295081T3 (en) 2001-06-26 2019-02-18 Amgen Inc Antibodies to OPGL
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
HUE035618T2 (en) 2010-01-15 2018-05-28 Kirin Amgen Inc Antibody presentation and therapeutic regimens
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis

Also Published As

Publication number Publication date
GB8807803D0 (en) 1988-05-05
KR890014125A (ko) 1989-10-21
FR2629345A1 (fr) 1989-10-06
SE8901115D0 (sv) 1989-03-30
DK156589D0 (da) 1989-03-30
BE1001845A4 (fr) 1990-03-20
NL8900779A (nl) 1989-10-16
GB2218101A (en) 1989-11-08
DE3910323A1 (de) 1989-10-19
IL89804A0 (en) 1989-09-28
IT1232827B (it) 1992-03-05
JPH02117700A (ja) 1990-05-02
AU3228789A (en) 1989-10-05
IT8947794A0 (it) 1989-03-30
DK156589A (da) 1989-10-01
GB8907148D0 (en) 1989-05-10

Similar Documents

Publication Publication Date Title
SE8901115D0 (sv) Biologiskt aktiva proteiner
IT8547835A0 (it) Procedimento di purificazione di proteine ossee
DK478786A (da) Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DK0830376T3 (da) Fremgangsmåde til fremstilling af erythropoietin, som er fri for animalske proteiner
IT8467249A0 (it) Protesi valvolare cardiaca provvista di lembi valvolari di tessuto biologico
DE3587549D1 (de) Ergänzungstestverfahren von proteine bindenden enzymen.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
EA200000311A1 (ru) Новый белок иммунной системы - кау
MY102472A (en) Preparation of funtional human urokinase proteins.
DK31088D0 (da) Blodkoaguleringsnedsaettende peptidderivater
NO178682C (no) Fremgangsmåte for å stabilisere blodkoagulasjonsfaktorer, samt kontrollplasma og reagens for å bestemme biologisk aktivitet av blodkoagulasjonsfaktorer
DE68915715D1 (de) Membran-Blutoxygenator.
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
DK235687A (da) Tilberedninger til syntese af prostaglandiner og hydroxyfedtsyrer i biologiske systemer og anvendelse deraf
CA1267497C (en) PROTEIN RECOVERY
DE3686130D1 (de) Geschmackskontrolle von proteinhydrolysaten.
DE69822164D1 (de) Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
DE68909409D1 (de) Heilmitteldosierung zur verabreichung an fische.
DE68908046D1 (de) Instrument fuer inokulation von zwiebelschalen.
DE3775389D1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
BG44379A3 (en) Method for preparing of 9- chlor- 1, 5- benzothiazepine derivatives
FI881122A0 (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
DE3883044D1 (de) Wirkstoff zur tumorbekaempfung.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8901115-9

Effective date: 19910424